Registry for patients with Diffuse Intrinsic Pontine Glioma and Diffuse Midline Glioma
International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository
Children's Hospital Medical Center, Cincinnati · NCT03101813
This study is creating a registry to collect information and tissue samples from patients with Diffuse Intrinsic Pontine Glioma and Diffuse Midline Glioma to help improve how these tumors are diagnosed and treated.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1500 (estimated) |
| Sex | All |
| Sponsor | Children's Hospital Medical Center, Cincinnati (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Cincinnati, Ohio) |
| Trial ID | NCT03101813 on ClinicalTrials.gov |
What this trial studies
This registry aims to collect clinical information and tumor tissue samples from patients diagnosed with Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma (DMG). By establishing a central repository, researchers will gather data on the biology of these tumors to improve diagnosis and treatment methods. The registry will include both newly diagnosed and previously diagnosed patients, allowing for a comprehensive understanding of the disease. Data collected will include clinical, demographic, radiological, and pathological information, facilitating future research collaborations.
Who should consider this trial
Good fit: Ideal candidates for this registry include patients of any age with a current or past diagnosis of DIPG or DMG.
Not a fit: Patients without a diagnosis of DIPG or DMG will not benefit from participation in this registry.
Why it matters
Potential benefit: If successful, this registry could lead to improved diagnostic and treatment strategies for patients with DIPG and DMG.
How similar studies have performed: Other studies focusing on tumor registries have shown success in advancing research and treatment options for similar conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients of any age (living or deceased) with a diagnosis (either current or past) of a DIPG/DMG tumor * Unless the patient is deceased, all patients and/or one parent or legal guardian must provide written informed consent as well as HIPAA/release of information consent.
Where this trial is running
Cincinnati, Ohio
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States (RECRUITING)
Study contacts
- Principal investigator: Trent Hummel, MD — Children's Hospital Medical Center, Cincinnati
- Study coordinator: DIPG/DMG Operations Team
- Email: referrals@dipgregistry.org
- Phone: 1-877-349-8074
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Midline Glioma